
USD
$0.00
(0.00%
)At Close (As of Dec 5, 2025)
$178.38M
Market Cap
-
P/E Ratio
-0.45
EPS
$2.84
52 Week High
$0.38
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$67M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $9.4M |
| Capital Expenditures | $267K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $38M |
| Cashflow From Financing | $28M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $290K |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$98M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology firm headquartered in Brisbane, California, specializing in the development of transformative genomic medicines. Utilizing its innovative platform technologies in gene therapy, cell therapy, genome editing, and genome regulation, Sangamo is dedicated to addressing unmet medical needs and improving patient outcomes. The company's cutting-edge research focuses on advancing therapies for genetic and acquired diseases, positioning it as a pivotal player in the fast-evolving landscape of genomic medicine.